A team of researchers from Indiana University School of Medicine has uncovered a promising new way to fight prostate cancer, one of the most common and deadly cancers affecting men.
Their findings could eventually lead to new treatments for patients whose cancer no longer responds to current therapies.
Prostate cancer develops in the prostate gland, a small organ that is part of the male reproductive system. It is one of the most frequently diagnosed cancers in men around the world.
While many cases grow slowly and can be treated successfully when found early, some forms become aggressive and spread to other parts of the body. Advanced prostate cancer can be difficult to treat and remains a major cause of cancer-related deaths.
For many years, the main treatment for advanced prostate cancer has focused on reducing or blocking testosterone. Testosterone is a male hormone that helps prostate cancer cells grow and multiply. By lowering hormone levels or preventing cancer cells from using the hormone, doctors can often slow the disease.
However, this approach does not always work forever. Over time, many cancers adapt and continue growing despite hormone-blocking treatment. When this happens, patients have fewer treatment options available.
The new study explored a completely different strategy. Instead of targeting hormones, the researchers focused on the nutrients that cancer cells need to survive. Like healthy cells, cancer cells require a steady supply of nutrients to grow. However, because cancer cells divide rapidly, they often need much larger amounts of these nutrients.
One important group of nutrients is amino acids. Amino acids are the building blocks that help create proteins in the body. Proteins are essential for nearly every activity inside a cell.
Cancer cells depend heavily on amino acids to maintain their fast growth. This led researchers to ask an important question: what would happen if cancer cells could no longer access enough amino acids?
The research team was led by Dr. Kirk Staschke and Dr. Ronald C. Wek. They studied how prostate cancer cells respond when amino acids become scarce.
Their work focused on a protein called GCN2. Under normal conditions, GCN2 acts like a survival system for cells. When nutrients are running low, GCN2 helps cells adjust and find ways to keep functioning. It essentially helps cells cope with nutritional stress.
The scientists believed that if they could block GCN2, cancer cells would struggle to survive when amino acids were limited. Their experiments showed that this idea was partly correct. When GCN2 was blocked, prostate cancer growth slowed significantly. However, the cancer cells did not die completely.
This result suggested that the cancer had another way to protect itself. The researchers continued investigating and discovered a second survival pathway involving a protein called p53.
The finding was unexpected. In many cancers, p53 is often damaged or inactive. In fact, p53 is sometimes called the “guardian of the genome” because it normally helps protect cells from becoming cancerous.
When p53 is lost or mutated, cancer can grow more easily. However, in prostate cancer, the researchers found that p53 was still functioning and helping cancer cells survive difficult conditions.
Rather than allowing cells to keep growing at full speed, p53 helped them slow down and conserve resources. It also supported their ability to find and use available nutrients. In other words, when GCN2 was blocked, p53 stepped in and helped the cancer adapt.
The researchers then tested a new approach. Instead of blocking only GCN2, they blocked both GCN2 and p53 at the same time. The results were much stronger. Without either survival system, the cancer cells struggled to cope with nutrient shortages. Their ability to grow and survive was greatly reduced.
This discovery highlights an important weakness in prostate cancer. Cancer cells are often very adaptable and can switch between different survival strategies. By targeting multiple pathways at once, researchers may be able to prevent cancer from finding alternative ways to stay alive.
Although the research is still in the early stages and has not yet led to a treatment available for patients, the findings provide an exciting direction for future studies.
Scientists hope that drugs targeting both GCN2 and p53 could eventually be developed and tested in clinical trials. Such treatments might be especially valuable for patients whose cancer has stopped responding to hormone-based therapies.
Dr. Staschke described the approach as a new way of starving prostate cancer. By cutting off the cancer’s ability to respond to nutrient stress, researchers may be able to slow or stop tumor growth more effectively than current methods alone.
The study was also a collaborative effort involving graduate students Ricardo Cordova and Noah Sommers, along with researchers from Rutgers University and the University at Buffalo. Their work demonstrates how scientists from different institutions can combine their expertise to tackle complex health challenges.
While much more research is needed before this strategy can be used in hospitals, the findings offer new hope in the fight against prostate cancer. By understanding exactly how cancer cells survive and adapt, scientists are uncovering new weaknesses that could become powerful targets for future treatments.
Every new discovery brings researchers one step closer to developing better therapies and improving outcomes for the many men affected by this disease each year.
If you care about prostate cancer, please read studies about 5 types of bacteria linked to aggressive prostate cancer, and new strategy to treat advanced prostate cancer.
For more information about prostate cancer, please see recent studies about new way to lower risk of prostate cancer spread, and results showing three-drug combo boosts survival in metastatic prostate cancer.
The study was published in the journal Cell Reports.
Copyright © 2026 Knowridge Science Report. All rights reserved.
